MHRA paediatric investigation plan
Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein, (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein,)
MHRA paediatric investigation plan MHRA-100470-PIP01-22 · Agreement
Key facts
| PIP number | MHRA-100470-PIP01-22 |
|---|---|
| Active substances | Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein,, Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid carrier protein,, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid carrier protein,, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid carrier protein,, Neisseria meningitidis serogroup B fHbp subfamily A,, Neisseria meningitidis serogroup B fHbp subfamily B, |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of Invasive disease caused by Neisseria meningitidis group A, B, C, W and Y |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Nov 2, 2022 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: